Patient and transplant characteristics
| . | Study cohort (n = 1004), % . | PBSC (n = 571), % . | BM (n = 433), % . |
|---|---|---|---|
| HLA-DPB1 matching | |||
| Matched | 210 (21) | 109 (19) | 101 (23) |
| Permissive mismatches | 443 (44) | 250 (44) | 193 (45) |
| Nonpermissive mismatches, GVH | 184 (18) | 120 (21) | 64 (15) |
| Nonpermissive mismatches, HVG | 167 (17) | 92 (16) | 75 (17) |
| HLA-DQ matching | |||
| Matched | 955 (95) | 549 (96) | 406 (94) |
| Mismatched at 1 allele level | 49 (5) | 22 (4) | 27 (6) |
| HLA-DRB3/4/5 matching | |||
| Matched | 925 (92) | 532 (93) | 393 (91) |
| Mismatched at 1 or 2 allele levels | 79 (8) | 39 (7) | 40 (9) |
| Patient age (y) | |||
| ≤55 | 518 (52) | 281 (49) | 237 (55) |
| >55 | 486 (48) | 290 (51) | 196 (45) |
| DRI | |||
| Very high | 62 (6) | 29 (5) | 33 (8) |
| High | 259 (26) | 135 (24) | 124 (29) |
| Intermediate | 497 (50) | 286 (50) | 211 (49) |
| Low | 142 (14) | 97 (17) | 45 (10) |
| Unknown | 44 (4) | 24 (4) | 20 (5) |
| Donor/recipient CMV serostatus | |||
| NR/NR | 130 (13) | 87 (15) | 43 (10) |
| R/R | 333 (33) | 187 (33) | 146 (34) |
| R/NR | 60 (6) | 41 (7) | 19 (4) |
| NR/R | 471 (47) | 248 (43) | 223 (52) |
| Undetermined | 10 (1) | 8 (1) | 2 (0.5) |
| Donor/recipient ABO incompatibility | |||
| None | 429 (43) | 240 (42) | 189 (44) |
| Major | 323 (32) | 181 (32) | 142 (33) |
| Minor | 243 (24) | 143 (25) | 100 (23) |
| Undetermined | 9 (1) | 7 (1) | 2 (0.5) |
| Donor/recipient sex | |||
| M/M or F/F | 559 (56) | 324 (57) | 235 (54) |
| F/M or M/F | 440 (44) | 244 (43) | 196 (45) |
| Undetermined | 5 (0.5) | 3 (0.5) | 2 (0.5) |
| Donor age (y) | |||
| ≤30 | 471 (47) | 272 (48) | 199 (46) |
| >30 | 514 (51) | 287 (50) | 227 (52) |
| Undetermined | 19 (2) | 12 (2) | 7 (2) |
| Conditioning intensity | |||
| Reduced intensity | 355 (35) | 254 (44) | 101 (23) |
| Myeloablative | 649 (65) | 317 (56) | 332 (77) |
| . | Study cohort (n = 1004), % . | PBSC (n = 571), % . | BM (n = 433), % . |
|---|---|---|---|
| HLA-DPB1 matching | |||
| Matched | 210 (21) | 109 (19) | 101 (23) |
| Permissive mismatches | 443 (44) | 250 (44) | 193 (45) |
| Nonpermissive mismatches, GVH | 184 (18) | 120 (21) | 64 (15) |
| Nonpermissive mismatches, HVG | 167 (17) | 92 (16) | 75 (17) |
| HLA-DQ matching | |||
| Matched | 955 (95) | 549 (96) | 406 (94) |
| Mismatched at 1 allele level | 49 (5) | 22 (4) | 27 (6) |
| HLA-DRB3/4/5 matching | |||
| Matched | 925 (92) | 532 (93) | 393 (91) |
| Mismatched at 1 or 2 allele levels | 79 (8) | 39 (7) | 40 (9) |
| Patient age (y) | |||
| ≤55 | 518 (52) | 281 (49) | 237 (55) |
| >55 | 486 (48) | 290 (51) | 196 (45) |
| DRI | |||
| Very high | 62 (6) | 29 (5) | 33 (8) |
| High | 259 (26) | 135 (24) | 124 (29) |
| Intermediate | 497 (50) | 286 (50) | 211 (49) |
| Low | 142 (14) | 97 (17) | 45 (10) |
| Unknown | 44 (4) | 24 (4) | 20 (5) |
| Donor/recipient CMV serostatus | |||
| NR/NR | 130 (13) | 87 (15) | 43 (10) |
| R/R | 333 (33) | 187 (33) | 146 (34) |
| R/NR | 60 (6) | 41 (7) | 19 (4) |
| NR/R | 471 (47) | 248 (43) | 223 (52) |
| Undetermined | 10 (1) | 8 (1) | 2 (0.5) |
| Donor/recipient ABO incompatibility | |||
| None | 429 (43) | 240 (42) | 189 (44) |
| Major | 323 (32) | 181 (32) | 142 (33) |
| Minor | 243 (24) | 143 (25) | 100 (23) |
| Undetermined | 9 (1) | 7 (1) | 2 (0.5) |
| Donor/recipient sex | |||
| M/M or F/F | 559 (56) | 324 (57) | 235 (54) |
| F/M or M/F | 440 (44) | 244 (43) | 196 (45) |
| Undetermined | 5 (0.5) | 3 (0.5) | 2 (0.5) |
| Donor age (y) | |||
| ≤30 | 471 (47) | 272 (48) | 199 (46) |
| >30 | 514 (51) | 287 (50) | 227 (52) |
| Undetermined | 19 (2) | 12 (2) | 7 (2) |
| Conditioning intensity | |||
| Reduced intensity | 355 (35) | 254 (44) | 101 (23) |
| Myeloablative | 649 (65) | 317 (56) | 332 (77) |
F, female; M, male; NR, nonreactive; R, reactive.